UNITED STATESSECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549



---

FORM 8-K

---



CURRENT REPORT



Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934



May 15, 2007 (May 15, 2007)

Date of Report (Date of earliest event reported)



---

AVAX TECHNOLOGIES, INC.

(Exact name of Registrant as specified in its charter)



Delaware
        000-29222
        13-3575874(State or other jurisdiction
of incorporation)
        (Commission File Number)
        (IRS Employer
Identification Number)




2000 Hamilton Street

Suite 204

Philadelphia, PA  19130

(Address of principal executive offices, including zip code)



(215) 241-9760

(Registrants telephone number, including area code)



---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).



oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).



oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).



oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).





---

Item 7.01
        Regulation FD Disclosure.




On May 15, 2007, Richard P.
Rainey, President of the Company, will make a presentation at the Acumen Biofin Rodman & Renshaw 4th Annual Global
Health Care Conference in Monte Carlo. The presentation will include an update on the Companys corporate and development
programs, including an overview of the Companys planned Phase III trial in Melanoma. A web-cast of the Companys
presentation may be accessed via the events web site link at http://www.wsw.com/webcast/rrshq11/avxt.



The slides from the presentation
are attached as Exhibit 99.1. Those slides are furnished pursuant to Item 7.01 and the information contained therein is
not filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the
liabilities under that Section. Furthermore, the information in Exhibit 99.1 is not incorporated by reference into the
Companys filings under the Securities Act of 1933.



Except for statements that are
historical, the statements in this release are forward-looking statements that are made pursuant to the safe harbor
provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements involve significant risks and uncertainties, including those risks outlined in the Safe
Harbor slide of Exhibit 99.1 and other risks incorporated by reference from the Companys annual report on Form
10-KSB for the year ended December 31, 2006, and in light of the significant uncertainties inherent in such statements, the
inclusion of such information should not be regarded as a representation by the Company that the objectives and plans of the
Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking
statements. The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements or
to reflect the occurrence of unanticipated events.



Item 9.01
        Financial Statements and Exhibits.




(d)
        Exhibits.




The following exhibit is filed with this report:




99.1
        Slideshow accompanying the May 15, 2007, presentation.


-1-

---

SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.





AVAX TECHNOLOGIES, INC.Date:  May 15, 2007
        
        By:
        /s/   Richard P. RaineyName:
        Richard P. RaineyTitle:
        President






-2-

---